Журнал кардиореспираторных исследований. Special Issue 1.1.(сборник статей)
Subject of the article
RELEVANCE AND PROSPECTS OF BIOLOGIC THERAPY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (170-173)
Authors
Z.B. Babamuradova, R.V. Gorenkov
Institution
Samarkand State Medical University
Abstract
Our research group studied the presence and amount of tumour necrosis factor in the blood, before and after treatment with monoclonal antibodies. In the course of treatment, our research team observed clinical and laboratory improvement after application of monoclonal antibodies, unlike other drugs such as steroid hormones or cytostatics
Key words
monoclonal antibodies, systemic lupus, rheumatology, cytostatics, innovational treatment
Literature
Askanase A, Reddy A, Buyon JP, et al. Favorable clinical response to belimumab at three months [abstract]. Arthritis Rheum. 2013;65(10):1574. 2. Babamuradova Z. B., Shavazi N. N. Assessment of the efficacy and safety of biological agents in rheumatoid arthritis // Journal of Advanced Medical and Dental Sciences Research. – 2021. – Т. 9. – №. 6. – С. 26-31. 3. Babamuradova Z. B., Shodikulova G. Z., Mirzaev O. V. Treatment of patients with undifferentiated connective tissue dysplasia in mitral valve prolapse with varying degrees of mitral regurgitation //European science review. – 2018. – №. 3-4. – С. 140-143. 4. Ginzler E, Wallace D, Merill J. Disease control and safety of Belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol. 2014;41(2):300–9. doi: 10.3899/jrheum.121368 5. Shavazi N. N., Babamuradova Z. B. Efficiency of the risk scale of extreme premature labor //Journal of Advanced Medical and Dental Sciences Research. – 2021. – Т. 9. – №. 6. – С. 21-25. 6. Shodikulova G. Z., Mirzaev O. V., Babamuradova Z. B. Prevalence of clinical options of undifferentiated connective tissue dysplasia in uzbek population //European Research: innovation in science, education and technology. – 2020. – С. 90-92. 7. Yazdany J, Erkan D, Sanchez-Guerrero J, et al. Post-marketing experience with belimumab in U.S. Lupus Centers: data from the Lupus Clinical Trials Consortium, Inc. (LCTC) National Patient Registry [abstract]. Arthritis Rheum. 2013;65(10):1605.